Free tool
FAERS Monitor: Trelstar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021288 or its brand name (Trelstar, Triptorelin Pamoate). Reports on generic versions are filed under their own applications.
Reports
2,599
Serious
1,873
72% of reports
Hospitalization
623
Death reported
532
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death406
- fatigue128
- hot flush127
- inappropriate schedule of product administration110
- off label use107
- asthenia89
- prostatic specific antigen increased89
- malignant neoplasm progression82
- product dose omission issue82
- disease progression78
- terminal state74
- drug ineffective73
- nausea70
- dizziness63
- fall63
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 7 |
| 2007 | 16 |
| 2008 | 7 |
| 2009 | 5 |
| 2010 | 19 |
| 2011 | 33 |
| 2012 | 53 |
| 2013 | 28 |
| 2014 | 47 |
| 2015 | 70 |
| 2016 | 57 |
| 2017 | 58 |
| 2018 | 138 |
| 2019 | 157 |
| 2020 | 221 |
| 2021 | 205 |
| 2022 | 251 |
| 2023 | 268 |
| 2024 | 331 |
| 2025 | 383 |
| 2026 | 237 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,560 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| terminal stateSignal | 74 | 90.5 | 72.2 | 6,393 |
| prostatic specific antigen increasedSignal | 89 | 52.6 | 42.9 | 4,429 |
| hot flushSignal | 127 | 13.7 | 11.5 | 1,480 |
| malignant neoplasm progressionSignal | 82 | 6.5 | 5.2 | 376 |
| disease progressionSignal | 78 | 5.3 | 4.3 | 272 |
| inappropriate schedule of product administrationSignal | 110 | 4.9 | 4.1 | 345 |
| deathSignal | 406 | 3.8 | 3.5 | 876 |
| product dose omission issueSignal | 82 | 2.3 | 1.8 | 57 |
| asthenia | 89 | 1.9 | 1.6 | 39 |
| fall | 63 | 1.5 | 1.2 | 11 |
| fatigue | 128 | 1.3 | 1.1 | 11 |
| dizziness | 63 | 1.0 | 0.8 | 0 |
| off label use | 107 | 1.0 | 0.8 | 0 |
| nausea | 70 | 0.7 | 0.6 | 8 |
| drug ineffective | 73 | 0.4 | 0.4 | 52 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.